Satoshi Yoshioka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8935560/publications.pdf

Version: 2024-02-01

687363 713466 37 498 13 21 citations h-index g-index papers 40 40 40 1289 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood, 2006, 108, 382-389.	1.4	71
2	C/EBPβ Is Involved in the Amplification of Early Granulocyte Precursors during Candidemia-Induced "Emergency―Granulopoiesis. Journal of Immunology, 2012, 189, 4546-4555.	0.8	71
3	Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma. Annals of Hematology, 2017, 96, 1-8.	1.8	32
4	Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology–oncology unit. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 209-216.	2.9	30
5	Parathyroid Hormone Enhances Hematopoietic Expansion Via Upregulation of Cadherin-11 in Bone Marrow Mesenchymal Stromal Cells. Stem Cells, 2014, 32, 2245-2255.	3.2	29
6	Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transplantation, 2005, 36, 667-674.	2.4	26
7	Chimerism of bone marrow mesenchymal stem/stromal cells in allogeneic hematopoietic cell transplantation. Chimerism, 2013, 4, 78-83.	0.7	21
8	Expression of multiple leukemic stem cell markers is associated with poor prognosis in <i>de novo</i> acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2144-2151.	1.3	20
9	Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study. International Journal of Hematology, 2020, 112, 674-689.	1.6	19
10	CCAAT/Enhancer-Binding Protein \hat{I}^2 Expressed by Bone Marrow Mesenchymal Stromal Cells Regulates Early B-Cell Lymphopoiesis. Stem Cells, 2014, 32, 730-740.	3.2	17
11	The role of growth differentiation factor 15 in the pathogenesis of primary myelofibrosis. Cancer Medicine, 2015, 4, 1558-1572.	2.8	16
12	Isolation of mesenchymal stromal/stem cells from small-volume umbilical cord blood units that do not qualify for the banking system. International Journal of Hematology, 2015, 102, 218-229.	1.6	15
13	Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine. Cancer Science, 2021, 112, 5034-5045.	3.9	15
14	Isolation of mesenchymal stromal/stem cells from cryopreserved umbilical cord blood cells. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 1-8.	0.8	14
15	Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. Clinical Cancer Research, 2021, 27, 4825-4835.	7.0	14
16	Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 387-394.	2.4	13
17	Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group. Annals of Hematology, 2019, 98, 2815-2823.	1.8	11
18	Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells. International Journal of Hematology, 2017, 105, 587-597.	1.6	10

#	Article	IF	CITATIONS
19	Successful Treatment of Herpes Simplex Virus (HSV)-1-associated Hemophagocytic Lymphohistiocytosis (HLH) with Acyclovir: A Case Report and Literature Review. Internal Medicine, 2017, 56, 2919-2923.	0.7	10
20	Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. International Journal of Hematology, 2021, 113, 840-850.	1.6	7
21	Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies. Scientific Reports, 2020, 10, 21418.	3.3	6
22	Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis. Leukemia and Lymphoma, 2016, 57, 1945-1948.	1.3	4
23	Stochastic model based on preharvest peripheral CD34â€positive cell count and collection efficiency predicting processed blood volume in peripheral hematopoietic stem cell apheresis. Transfusion, 2019, 59, 671-680.	1.6	4
24	Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation. Blood Advances, 2020, 4, 667-671.	5.2	4
25	Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia. Annals of Hematology, 2021, 100, 217-228.	1.8	4
26	Adultâ€onset primary cyclic autoimmune neutropenia: a case report. Transfusion, 2018, 58, 884-890.	1.6	3
27	The impact of early diagnosis on the prognosis of extranodal NK/T-cell lymphoma with massive lung involvement: a case report. BMC Pulmonary Medicine, 2019, 19, 48.	2.0	3
28	Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 400-410.	2.4	3
29	Human Mesenchymal Stem Cell Therapy for Acute Graft Versus Host Disease. Translational Medicine (Sunnyvale, Calif), 2016, 6, .	0.4	2
30	Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis. Transplantation and Cellular Therapy, 2021, 27, 1005.e1-1005.e8.	1.2	1
31	Bortezomib Attenuates Adhesion of B Cell Precursor Acute Lymphoblastic Lleukemia Cells to Bone Marrow Mesenchymal Stromal/Stem Cells Via Regulating SPARC Expression. Blood, 2015, 126, 786-786.	1.4	1
32	Auer-rod-like Inclusions in the Mature Neutrophils of a T-acute Lymphoblastic Leukemia Patient. Internal Medicine, 2018, 57, 3057-3058.	0.7	0
33	Clinical outcomes of hepatitis B or C virus infections in patients with malignant lymphoma receiving autologous stem cell transplantation: on behalf of the Adult Lymphoma Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT). British Journal of Haematology, 2019, 186, e170-e175.	2.5	0
34	Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for systemic Epstein-Barr virus-positive T-cell lymphoma of childhood. Bone Marrow Transplantation, 2021, 56, 1743-1745.	2.4	0
35	INACTIVATION OF COMPLEMENT IS REQUIRED FOR PRECISE EVALUATION OF Anti-HLA ANTIBODIES: AN IMPORTANT LESSON LEARNED FROM TWO CLINICAL CASES. Japanese Journal of Transfusion and Cell Therapy, 2013, 59, 462-469.	0.2	0
36	T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis. Journal of Clinical and Experimental Hematopathology: JCEH, 2015, 55, 17-21.	0.8	0

3

SATOSHI YOSHIOKA

#	=	Article	IF	CITATIONS
3	7	Autologous hematopoietic cell transplantation for myeloma patients with hepatitis B virus or hepatitis C virus in the era of novel agents. Bone Marrow Transplantation, 2022, , .	2.4	0